{
    "organizations": [],
    "uuid": "b5881f00853c6bda80b6525b411dbc4ef2ccabc4",
    "author": "",
    "url": "https://www.reuters.com/article/brief-us-fda-grants-priority-review-for/brief-u-s-fda-grants-priority-review-for-supplemental-new-drug-application-for-xtandi-idUSASC09SVR",
    "ord_in_thread": 0,
    "title": "BRIEF-U.S. FDA Grants Priority Review For Supplemental New Drug Application For Xtandi",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 19, 2018 / 8:50 PM / Updated 12 minutes ago BRIEF-U.S. FDA Grants Priority Review For Supplemental New Drug Application For Xtandi Reuters Staff 1 Min Read March 19 (Reuters) - Astellas Pharma Inc: * U.S. FDA GRANTS PRIORITY REVIEW FOR A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR XTANDI® (ENZALUTAMIDE) IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) * ASTELLAS PHARMA INC - ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE ASSIGNED BY FDA IS JULY 2018​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-19T22:49:00.000+02:00",
    "crawled": "2018-03-19T23:09:07.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "fda",
        "grant",
        "priority",
        "review",
        "supplemental",
        "new",
        "drug",
        "application",
        "xtandi",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "astellas",
        "pharma",
        "inc",
        "fda",
        "grant",
        "priority",
        "review",
        "supplemental",
        "new",
        "drug",
        "application",
        "snda",
        "enzalutamide",
        "prostate",
        "cancer",
        "crpc",
        "astellas",
        "pharma",
        "inc",
        "drug",
        "user",
        "fee",
        "act",
        "pdufa",
        "goal",
        "date",
        "assigned",
        "fda",
        "july",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}